Based on the information available at this point in time, it is doubtful the SP will ever go below $1. Even with moderate success from this trial, DCVax-L will have a value for a BP as there's ample evidence that it will work well in a combination with other drugs. The minimum value I have assessed as a potential buy-out price in the event that there's just a decent improvement in OS from DCVax-L by itself is around $1.5-2B. Again, this is just what I have arrived at looking at the interim blinded report and the speeches of Dr's Ashkan and Liau have arrived at and should be taken with some reservation. I am confident in them and I have been adding on dips.
Funny, I already know exactly what you will say if TLD is released and is spectacular. You'll find some minuscule sub-group that doesn't benefit or has some minor inconvenience and pretend they are who needs it most and go on about how you have always cared about them. It will be like coal advocates bemoaning the number of birds killed by wind turbines but neglecting to note that wind power kills the least birds per unit of power of any generation method. Or bemoaning that some handicapped individuals will not be able to use plastic straws if there is a ban to protect life on Earth.
News 
Market Data 
Discover 
